Open AccessMODERN POSSIBILITIES OF MEDICAL TREATMENT OF OVERACTIVE BLADDER IN WOMEN
Author(s) -
Inna Apolikhina,
А. С. Чочуева,
A.S. Saidova,
Екатерина Горбунова
Publication year - 2017
Publication title -
medicinskij sovet
Language(s) - English
Resource type - Journals
eISSN - 2658-5790
pISSN - 2079-701X
DOI - 10.21518/2079-701x-2017-2-122-127
Subject(s) - mirabegron , overactive bladder , medicine , urination , urology , placebo , urinary urgency , constipation , agonist , urinary bladder , urinary incontinence , urinary system , receptor , alternative medicine , pathology
Overactive bladder (OAB) is a serious urination disorder which affects at least 17% of the population above 40 years old, of which 56% are women and 44% are men. M-cholinoblockers are the first line therapy and the main treatment for OAB. However, their side effects, along with low efficacy, force women to stop taking the drugs. Activation of beta-3-adrenergic receptors is known toreduce the tone of detrusor muscle in the bladder. This resulted in the invention of mirabegron (Mirabegron, Betmiga, Astellas Pharma Europe, Netherlands), the first drug of a new pharmacologic group (beta-3 adrenergic agonists) for the treatment of OAB. A selective beta-3 agonist, mirabegron has no side effects such as dry mouth, increased intraocular pressure or constipation. Numerous clinical studies demonstrated a reduction in the number of episodes of urinary incontinence and frequent urination in the mirabegron group compared to the placebo group.